Breast Cancer: ARO & DARPA. 2022 manuscript. 2023
Post# of 154262
(Total Views: 517)
Posted On: 09/25/2024 9:00:21 PM
Breast Cancer: ARO & DARPA.
2022 manuscript. 2023 pub.
After developing a model for high and low CCR5 expression, as well as the nuclear internalization of the receptor in cell lines, we recruited 54 mBC patients to study CCR5 in TACs circulating in the bloodstream. In contrast with cell lines, we found that CCR5 in both CTCs and CAMLs appear mostly as CCR5 pools when present on the surface of the cell (Figs. 3a-c). However, internalized CCR5 signal also appeared as CCR5 pools, but more often appeared as diffuse signal that generally overlapped with the nucleus (Fig. 3d). In the patients tested (n = 54), 70% (n = 38) had CCR5 positive CAMLs and 41% (n = 22) had CCR5 positive CTCs, with positivity defined as ≥ 1 pool. We also found that when CCR5 is present on TACs, it is predominantly located on the surface of the cell. Moreover, we found that with CCR5 + CAMLs, 73% of the CCR5 signal on the cell surface and 20% being internal, with 7% pools appearing translocated to the nucleus. In CTCs, 69% of the CCR5 signal was on the cell surface, 23% was internal, and 8% of pools were translocated to the nucleus (Additional file 1: Fig. S4). Patients that had no TACs also had no CCR5 pools according to our analysis."
This work was supported by a Maryland (TEDCO) MTTCF award, grant R01-CA154624 from the National Cancer Institute, and the U.S. Army Research Office (ARO) and the Defense Advanced Research Projects Agency (DARPA) (W911NF-14-C-0098).
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9125938/
__________
Good breast cancer / CCRS publication.
& we know where our large molecule binds to, overthrowing Rantes.
Couldn't get that hold lifted fast enough.
ARO & DARPA know about us.
2022 manuscript. 2023 pub.
After developing a model for high and low CCR5 expression, as well as the nuclear internalization of the receptor in cell lines, we recruited 54 mBC patients to study CCR5 in TACs circulating in the bloodstream. In contrast with cell lines, we found that CCR5 in both CTCs and CAMLs appear mostly as CCR5 pools when present on the surface of the cell (Figs. 3a-c). However, internalized CCR5 signal also appeared as CCR5 pools, but more often appeared as diffuse signal that generally overlapped with the nucleus (Fig. 3d). In the patients tested (n = 54), 70% (n = 38) had CCR5 positive CAMLs and 41% (n = 22) had CCR5 positive CTCs, with positivity defined as ≥ 1 pool. We also found that when CCR5 is present on TACs, it is predominantly located on the surface of the cell. Moreover, we found that with CCR5 + CAMLs, 73% of the CCR5 signal on the cell surface and 20% being internal, with 7% pools appearing translocated to the nucleus. In CTCs, 69% of the CCR5 signal was on the cell surface, 23% was internal, and 8% of pools were translocated to the nucleus (Additional file 1: Fig. S4). Patients that had no TACs also had no CCR5 pools according to our analysis."
This work was supported by a Maryland (TEDCO) MTTCF award, grant R01-CA154624 from the National Cancer Institute, and the U.S. Army Research Office (ARO) and the Defense Advanced Research Projects Agency (DARPA) (W911NF-14-C-0098).
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9125938/
__________
Good breast cancer / CCRS publication.
& we know where our large molecule binds to, overthrowing Rantes.
Couldn't get that hold lifted fast enough.
ARO & DARPA know about us.
(10)
(0)